

[Erythromycin](#)

Not recommended as an essential medicine

Section:

[6. Anti-infective medicines 6.2. Antibacterials 6.2.2. Watch group antibiotics](#)

ATC codes: [J01FA01](#)

EMLc

Indication

Bacterial infection of unspecified site ICD11 code: [1C81](#)

INN

Erythromycin

Medicine type

Chemical agent

Antibiotic groups

[WATCH](#)

List type

Core

Formulations

Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)

Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)

Oral > Solid: 250 mg (as stearate or ethylsuccinate)

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1987 ([TRS 770](#))

Changed in 2007 ([TRS 950](#))

Removed in 2017 ([TRS 1006](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

Medicines within the same pharmacological class can be used

Therapeutic alternatives limitations

The square box only applies to the listing of erythromycin on the EML

Therapeutic alternatives limitations for EMLc

The square box does not apply to the listing of erythromycin on the EMLc

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Erythromycin](#)

DrugBank

[Erythromycin](#)

Summary of evidence and Expert Committee recommendations

Erythromycin was removed from the EML and EMLc following the comprehensive review of antibiotics by the Expert Committee in 2017. However, it is noted in the Model Lists as an alternative to clarithromycin for treatment of pharyngitis